We used a custom Nanostring panel to profile the expression of cancer/immune genes (Supplementary information, Table S3) in available pre-treatment tumors from 23 patients receiving combination anti-CTLA-4/PD-1 blockade for advanced melanoma (Andrews et al, manuscript in preparation) in a regimen that is often prescribed in the context of resistance to anti-PD-1 mAb. The gene discussed is CTLA4; the disease is cancer.